Perspective Therapeutics CATX Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Lantheus HoldingsLNTH

$6.19M-79.2%

CytomX TherapeuticsCTMX

——

OkloOKLO

——

Other financials

Income statement

See full

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

See full

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

See full

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

See full

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

See full

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

See full

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's indefinite-lived research and development assets?: Perspective Therapeutics (CATX) reported indefinite-lived research and development assets of $40M in Q1 2026.
How has Perspective Therapeutics's indefinite-lived research and development assets changed year-over-year?: Perspective Therapeutics's indefinite-lived research and development assets decreased by 20.0% year-over-year, from $50M to $40M.